Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) FCF Margin (2016 - 2025)

Historic FCF Margin for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to 626.21%.

  • Seres Therapeutics' FCF Margin changed N/A to 626.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 6657.55%, marking a year-over-year increase of 2408315100.0%. This contributed to the annual value of 99.21% for FY2023, which is 32486700.0% up from last year.
  • Per Seres Therapeutics' latest filing, its FCF Margin stood at 626.21% for Q3 2025.
  • In the past 5 years, Seres Therapeutics' FCF Margin ranged from a high of 626.21% in Q3 2025 and a low of 75587.5% during Q4 2023
  • Its 4-year average for FCF Margin is 9885.75%, with a median of 1766.23% in 2022.
  • Data for Seres Therapeutics' FCF Margin shows a peak YoY increase of 43324500bps (in 2023) and a maximum YoY decrease of -698077100bps (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows Seres Therapeutics' FCF Margin stood at 740.08% in 2021, then tumbled by -681bps to 5779.79% in 2022, then plummeted by -1208bps to 75587.5% in 2023, then soared by 101bps to 626.21% in 2025.
  • Its FCF Margin stands at 626.21% for Q3 2025, versus 75587.5% for Q4 2023 and 19694.19% for Q3 2023.